Initial Workup for Sinus Bradycardia

Definition and Initial Assessment

The American College of Cardiology recommends a comprehensive history and physical examination to identify potential underlying causes and assess symptom severity in patients with sinus bradycardia 1
A 12-lead ECG is essential to document rhythm, rate, and conduction, and to screen for structural heart disease or systemic illness in patients with sinus bradycardia 1

Medications such as beta blockers 2, non-dihydropyridine calcium channel blockers 3, digoxin 3, and sodium-channel and potassium-channel blocking antiarrhythmic drugs 3 should be thoroughly reviewed as potential causes of sinus bradycardia 4, 3
Laboratory tests such as thyroid function tests 3, electrolytes (particularly potassium) 2, pH (acidosis) 4, and Lyme titer when clinically indicated 5 should be considered based on clinical suspicion 5
Other potentially reversible causes to evaluate include elevated intracranial pressure 4, acute myocardial infarction 1, severe hypothermia 4, obstructive sleep apnea 4, and hypoxemia or hypercarbia [4] [4, 3]

Cardiac rhythm monitoring is crucial to establish correlation between heart rate/conduction abnormalities and symptoms in patients with sinus bradycardia 1
The type of monitor should be selected based on symptom frequency, with options including Holter monitor (24-72 hours) for frequent symptoms 6, event recorder or mobile cardiac telemetry for less frequent symptoms 6, and implantable cardiac monitor for very infrequent symptoms (>30 days between episodes) 5

Patients with symptomatic sinus bradycardia secondary to a reversible cause should first be managed by addressing the underlying condition 4, 3
Permanent pacing should be considered only after reversible causes have been excluded or when they cannot be adequately managed 7
In acute settings with hemodynamic compromise, temporary interventions may be needed while completing the diagnostic workup 7

The American Heart Association recommends reviewing all negative chronotropic agents, including beta-blockers, non-dihydropyridine calcium channel blockers, digoxin, and antiarrhythmic drugs, as they may contribute to sinus bradycardia 8
The American College of Cardiology suggests considering dose reduction or discontinuation of these medications if not essential, such as switching beta-blockers to ACE inhibitors or ARBs for hypertension 8
Electrolyte abnormalities, including potassium, calcium, and magnesium, should be evaluated and corrected as they may contribute to sinus bradycardia 8
The European Society of Cardiology recommends troponin and cardiac biomarkers testing if acute myocardial infarction is suspected, especially in cases of inferior MI causing vagal stimulation 9

Atropine 0.5-1 mg IV may be used to increase sinus rate in symptomatic patients with hemodynamic compromise, but should not be used in heart transplant patients without autonomic reinnervation 8
Temporary pacing is indicated if medications fail to increase heart rate in symptomatic patients with hemodynamic compromise 8, 9
In acute MI with sinus bradycardia and severe hypotension, IV atropine should be used first, followed by temporary pacing if unresponsive 9

The American College of Cardiology recommends that patients with acute heart failure symptoms, such as dyspnea or orthopnea, be evaluated for reversible causes of bradycardia 10
The American College of Cardiology suggests that atropine 0.5-1 mg IV be used as the initial treatment of choice for symptomatic or hemodynamically unstable patients, which can be repeated every 3-5 minutes to a maximum dose of 3 mg 10
The American College of Cardiology advises against using atropine in heart transplant patients without evidence of autonomic reinnervation, as it should not be used to treat sinus bradycardia in this population 10
The American College of Cardiology recommends considering alternative pharmacologic therapies, such as isoproterenol, dopamine, dobutamine, or epinephrine, if atropine fails and the patient is at low likelihood of coronary ischemia 10
The American College of Cardiology suggests that temporary pacing be considered if medications fail to increase heart rate in symptomatic patients with hemodynamic compromise 10
The American College of Cardiology recommends evaluating patients for acute infections as a potential reversible cause of bradycardia 10

For patients with acute altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or other signs of shock directly attributable to bradycardia, the American Heart Association recommends proceeding immediately to acute pharmacologic treatment 11
If symptoms are mild, the American Heart Association suggests focusing on identifying reversible causes first before any intervention 12, 13

The American College of Cardiology recommends atropine 0.5-1 mg IV as the first-line treatment for acute symptomatic bradycardia with hemodynamic compromise, repeated every 3-5 minutes to a maximum total dose of 3 mg 11
Atropine should NOT be used in heart transplant patients without evidence of autonomic reinnervation, as the transplanted heart lacks vagal innervation, according to the American Heart Association 11
If atropine fails and the patient is at low likelihood of coronary ischemia, alternative therapies such as isoproterenol, dopamine, dobutamine, or epinephrine may be considered, although the American College of Cardiology notes that use of atropine in acute coronary ischemia may worsen ischemia or increase infarct size 11, 14

The American Heart Association recommends temporary transvenous pacing if medications fail to increase heart rate in symptomatic patients with hemodynamic compromise, until a permanent pacemaker is placed or bradycardia resolves (Class IIa) 12, 13
Temporary transcutaneous pacing may be considered for severe symptoms or hemodynamic compromise as a bridge to transvenous pacing or permanent pacemaker (Class IIb), according to the American Heart Association 12, 13

For patients with symptoms likely attributable to sinus node dysfunction, a trial of oral theophylline may be considered to increase heart rate, improve symptoms, and help determine the potential effects of permanent pacing (Class IIb), as suggested by the American Heart Association 13

Permanent pacing is indicated (Class I) only when symptoms are directly attributable to sinus node dysfunction AND reversible causes have been excluded or adequately addressed, according to the American Heart Association 13
For symptomatic chronotropic incompetence, permanent pacing with rate-responsive programming is reasonable (Class IIa), as recommended by the American College of Cardiology 13

Asymptomatic sinus bradycardia requires no treatment and is common in young individuals and athletes, according to the European Society of Cardiology 15
In young patients, aggressive investigation for reversible causes must be completed before any consideration of permanent pacing, and the threshold for permanent pacing should be higher given the long-term implications of device therapy, as noted by the European Society of Cardiology 15